Alzheimer’s disease Pipeline Insights

DelveInsight reports that over 110 key companies are actively engaged in developing more than 120 treatment therapies for Alzheimer’s disease.

Alzheimer’s disease Overview:

Alzheimer’s disease (AD) is the leading cause of dementia, marked by progressive brain cell loss, cognitive decline, and loss of independence. It has complex causes, with aging, genetics, trauma, vascular issues, infections, and environmental factors among the main risks. Two major theories explain its development: the cholinergic and amyloid hypotheses.

Neuropathological changes include positive lesions (amyloid plaques, neurofibrillary tangles, and abnormal deposits) and negative lesions (neuronal and synaptic loss, brain atrophy). Additional factors like neuroinflammation, oxidative stress, and cholinergic neuron damage further drive degeneration.

Symptoms progress through three stages—preclinical, mild, and dementia-stage. Early signs often involve short-term memory loss, followed by impairments in judgment, problem-solving, organization, and abstract thinking, along with language and visuospatial difficulties. Later stages bring neuropsychiatric issues (apathy, agitation, psychosis), motor and sensory problems, sleep disturbances, and Parkinsonian-like features. In advanced disease, patients become fully dependent, with incontinence and loss of basic functions.

Request for a detailed insights report on Alzheimer’s disease pipeline insights @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Alzheimer’s disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer’s disease Therapeutics Market.

Key Takeaways from the Alzheimer’s disease Pipeline Report

• DelveInsight’s Alzheimer’s disease pipeline report highlights a dynamic landscape with over 110 active companies developing more than 120 potential therapies.

• Leading players include AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical, and others, all working to advance novel treatments.

• Key candidates in development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, and ALX-001, among others.

• Notably, in January 2023, the U.S. FDA granted accelerated approval to Leqembi, an amyloid beta-directed antibody that reduces amyloid plaques in the brain. This decision was based on early evidence of clinical benefit. By July 2023, Leqembi received full FDA approval following Phase 3 trial results confirming its effectiveness in slowing cognitive decline in patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease.

Alzheimer’s disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Alzheimer’s disease Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s disease treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer’s disease market.

Download our free sample page report on Alzheimer’s disease pipeline insights

Alzheimer’s disease Emerging Drugs

• AR1001: AriBio Co., Ltd.

• NE3107: BioVie

• LY3372689: Eli Lilly & Co.

• CT1812: Cognition Therapeutics

• ABBV-916: AbbVie Inc.

• ALX-001: Allyx Therapeutics, Inc.

Alzheimer’s disease Companies

Approximately 110 companies are engaged in developing therapies for Alzheimer’s disease, with AriBio Co., Ltd. and BioVie among those advancing drug candidates to the most progressed stage—Phase III clinical trials.

DelveInsight’s report covers around 120+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Alzheimer’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Alzheimer’s disease Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer’s disease Therapies and Key Companies: Alzheimer’s disease Clinical Trials and advancements

Alzheimer’s disease Pipeline Therapeutic Assessment

• Alzheimer’s disease Assessment by Product Type

• Alzheimer’s disease By Stage

• Alzheimer’s disease Assessment by Route of Administration

• Alzheimer’s disease Assessment by Molecule Type

Download Alzheimer’s disease Sample report to know in detail about the Alzheimer’s disease treatment market @ Alzheimer’s disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Alzheimer’s disease Current Treatment Patterns

4. Alzheimer’s disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Alzheimer’s disease Late-Stage Products (Phase-III)

7. Alzheimer’s disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Alzheimer’s disease Discontinued Products

13. Alzheimer’s disease Product Profiles

14. Alzheimer’s disease Key Companies

15. Alzheimer’s disease Key Products

16. Dormant and Discontinued Products

17. Alzheimer’s disease Unmet Needs

18. Alzheimer’s disease Future Perspectives

19. Alzheimer’s disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Alzheimer’s disease Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/